click below
click below
Normal Size Small Size show me how
Musculoskeletal
Generic | Brand | Pharmacologic Category | Common Indications | Essential Knowledge | EK Cont’d |
---|---|---|---|---|---|
tizanidine (PO) | Zanaflex | Alpha2 agonist | Spasticity | Key side effects: drowsiness, hypotension, dizziness, xerostomia, weakness | |
hydroxychloroquine (PO) | Plaquenil | Aminoquinolone | RA, SLE, malaria | KSE: retinal toxicity, rash, diarrhea. ON: use has been associated with cardiomyopathy, bone marrow suppression, and neuromuscular effects (i.e. myopathy, palsies, and progessive weakness) | |
colchicine (PO) | Colcrys | Antigout agent | Gout | Key side effects: diarrhea, nausea, vomiting, bone marrow suppression, myopathy (including rhabdomyolysis) | |
diclofenac (PO) | Voltaren | NSAID | OA, RA, acute pain | KSE: diarrhea, dyspepsia, abdominal pain; flatulence; nausea USBW: may increase the risk of serious (and potentially fatal) cardiovascular thrombotic events, MI, and stroke; may increase the risk for serious (and potentially fatal) GI —> | Adverse events including ulceration, bleeding, and perforation USBW (only for keto): indicated for short term use (≤ 5 days) ON: may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, HF, and cirrhosis) |
ibuprofen (PO) * | Motrin, Advil | NSAID | OA, RA, acute pain | KSE: diarrhea, dyspepsia, abdominal pain; flatulence; nausea USBW: may increase the risk of serious (and potentially fatal) cardiovascular thrombotic events, MI, and stroke; may increase the risk for serious (and potentially fatal) GI —> | Adverse events including ulceration, bleeding, and perforation USBW (only for keto): indicated for short term use (≤ 5 days) ON: may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, HF, and cirrhosis) |
meloxicam (PO) | Mobic | NSAID | OA, RA, acute pain | KSE: diarrhea, dyspepsia, abdominal pain; flatulence; nausea USBW: may increase the risk of serious (and potentially fatal) cardiovascular thrombotic events, MI, and stroke; may increase the risk for serious (and potentially fatal) GI —> | Adverse events including ulceration, bleeding, and perforation USBW (only for keto): indicated for short term use (≤ 5 days) ON: may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, HF, and cirrhosis) |
indomethacin (PO) | Indocin | NSAID | OA, RA, acute pain, gout | KSE: diarrhea, dyspepsia, abdominal pain; flatulence; nausea USBW: may increase the risk of serious (and potentially fatal) cardiovascular thrombotic events, MI, and stroke; may increase the risk for serious (and potentially fatal) GI —> | Adverse events including ulceration, bleeding, and perforation USBW (only for keto): indicated for short term use (≤ 5 days) ON: may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, HF, and cirrhosis) |
naproxen (PO) * | Naprosyn, Anaprox, Aleve | NSAID | OA, RA, acute pain, gout | KSE: diarrhea, dyspepsia, abdominal pain; flatulence; nausea USBW: may increase the risk of serious (and potentially fatal) cardiovascular thrombotic events, MI, and stroke; may increase the risk for serious (and potentially fatal) GI —> | Adverse events including ulceration, bleeding, and perforation USBW (only for keto): indicated for short term use (≤ 5 days) ON: may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, HF, and cirrhosis) |
ketorolac (PO, IV) | Toradol | NSAID | Pain | KSE: diarrhea, dyspepsia, abdominal pain; flatulence; nausea USBW: may increase the risk of serious (and potentially fatal) cardiovascular thrombotic events, MI, and stroke; may increase the risk for serious (and potentially fatal) GI —> | Adverse events including ulceration, bleeding, and perforation USBW (only for keto): indicated for short term use (≤ 5 days) ON: may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, HF, and cirrhosis) |
celecoxib (PO) | Celebrex | NSAID, COX-2 selective | OA, RA, acute pain | KSE: diarrhea, dyspepsia, abdominal pain; flatulence; nausea USBW: may increase the risk of serious (and potentially fatal) cardiovascular thrombotic events, MI, and stroke; may increase the risk for serious (and potentially fatal) GI —> | Adverse events including ulceration, bleeding, and perforation USBW (only for keto): indicated for short term use (≤ 5 days) ON: may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, HF, and cirrhosis) |
diclofenac (topical) * | Voltaren Gel | NSAID | OA | Key side effects: pruritus, rash | |
cyclobenzaprine (PO) | Flexeril | Skeletal muscle relaxant | Muscle spasm | KSE: drowsiness, dizziness, xerostomia, fatigue ON: use may cause prolonged cardiac arrhythmias, and tachycardia; CI within 14 days of MAOI inhibitor therapy | |
baclofen (PO) | - - - - | Skeletal muscle relaxant | Spasticity | KSE: drowsiness ON: drug abuse potential (carisoprodol only) | |
carisoprodol (PO) | Soma | Skeletal muscle relaxant | Muscle spasm | KSE: drowsiness ON: drug abuse potential (carisoprodol only) | |
methocarbamol (PO) | Robaxin | Skeletal muscle relaxant | Muscle spasm | KSE: drowsiness ON: drug abuse potential (carisoprodol only) | |
metaxalone (PO) | Skelaxin | Skeletal muscle relaxant | Muscle spasm | KSE: drowsiness ON: drug abuse potential (carisoprodol only) | |
lidocaine (transdermal *, IV) | Transdermal: Lidoderm, IV: Xylocaine | Transdermal: topical analgesic IV: antiarrhythmic | Transdermal: pain, IV: ventricular arrhythmias | KSE (transdermal): dermatitis, erythema, urticaria, skin depigmentation, skin edema KSE (IV): bradycardia ON: patch may remain in place for up to 12 hours in any 24-hr period, patch may be cut | |
allopurinol (PO) | Zyloprim | Xanthine oxidase Inhibitor | Gout | KSE: diarrhea, nausea, rash, leukopenia, thrombocytopenia ON: rare association with severe (and potentially fatal) allopurinol hypersensitivity syndrome (risk highest in certain Asian populations) | |
succinylcholine (IV) | Anectine | Depolarizing neuromuscular blocking agent | Neuromuscular blockade for intubation or procedures | KSE: hyperkalemia, myalgia, malignant hyperthermia (rare) USBW: acute rhabdomyolysis and hyperkalemia leading to cardiac arrest and death in pediatric patients with undiagnosed skeletal muscle disease |